Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis

Authors: Yongsheng Zhang, Lu Han, Jian Pang, Yang Wang, Fan Feng, Qiyu Jiang

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

The microRNA miR-452 has been shown to function as a tumor suppressor. However, the cellular mechanism and potential application of miR-452-mediated cancer suppression remain great unknown. This study aims to identify how miR-452 acts in regulating non-small cell lung cancer (NSCLC) proliferation and metastasis. Expression of miR-452 via adenoviral (Ad) vector inhibits the proliferation, invasion, and migration of NSCLC cells A549 or H460. Our data also shows that miR-452 down-regulates the expression of Bmi-1 as well as pro-survival or anti-apoptosis regulators Survivin, cIAP-1, and cIAP-2. By such gene interference, miR-452 modulates NSCLC cell epithelial–mesenchymal transition (EMT) and further disrupts their migration and invasion. Moreover, miR-452 blocks the activation of PI3K/AKT pathway, which is also required for EMT process. These data reveal that miR-452 treatment could be a novel target or strategy for NSCLC treatment.
Literature
1.
Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: lung cancer. N Engl J Med. 2008;359:1367–80.CrossRefPubMed
2.
Yoshida T, Zhang G, Smith MA, et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res. 2014;20:4059–74.CrossRefPubMedPubMedCentral
3.
Kang J, Kim E, Kim W, et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem. 2013;288:27343–57.CrossRefPubMedPubMedCentral
4.
5.
Qian B, Nag SA, Su Y, et al. miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets. 2013;13:519–41.CrossRefPubMed
6.
Xu X, Fan Z, Kang L, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–45.PubMedPubMedCentral
7.
He H, Wang L, Zhou W, et al. MicroRNA expression profiling in clear cell renal cell carcinoma: identification and functional validation of key miRNAs. PLoS One. 2015;10:e0125672.CrossRefPubMedPubMedCentral
8.
Liu C, Kelnar K, Vlassov AV, et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012;72:3393–404.CrossRefPubMed
9.
10.
Hu Q, Gong JP, Li J, et al. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 2014;15:5137–42.CrossRefPubMed
11.
Breuer RH, Snijders PJ, Sutedja GT, et al. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer. 2005;48:299–306.CrossRefPubMed
12.
Vrzalikova K, Skarda J, Ehrmann J, et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 2008;134:1037–42.CrossRefPubMed
13.
Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.CrossRefPubMed
14.
Hu J, Liu YL, Piao SL, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer. 2012;77:593–9.CrossRefPubMed
15.
Kuang BH, Zhang MQ, Xu LH, et al. Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients’ overall survival. Br J Cancer. 2013;109:1252–63.CrossRefPubMedPubMedCentral
16.
17.
He Z, Xia Y, Pan C, et al. Up-regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1. Cell Physiol Biochem. 2015;37:387–98.CrossRefPubMed
18.
Zhang F, Feng F, Yang PX, et al. Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell. Int J Biochem Cell Biol. 2012;44:320–6.CrossRefPubMed
19.
Cui L, Li M, Feng F, et al. MEIS1 functions as a potential AR negative regulator. Exp Cell Res. 2014;328:58–68.CrossRefPubMed
20.
Zhang P, Ma X, Song E, et al. Tubulin cofactor A functions as a novel positive regulator of ccRCC progression, invasion and metastasis. Int J Cancer. 2013;133:2801–11.CrossRefPubMed
21.
Lu Y, Feng F, Yang Y, et al. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells. Cell Signal. 2013;25:479–89.CrossRefPubMed
22.
Chen Y, Feng F, Gao XD, et al. MiRNA153 reduces effects of chemotherapeutic agents or small molecular kinase inhibitor in HCC cells. Curr Cancer Drug Targets. 2015;15:176–87.CrossRefPubMed
23.
Egloff AM, Rothstein ME, Seethala R, et al. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15:6529–40.CrossRefPubMedPubMedCentral
24.
Yang Q, Feng F, Zhang F, et al. LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell. Cell Signal. 2013;25:2652–60.CrossRefPubMed
25.
Feng F, Lu YY, Zhang F, et al. Long interspersed nuclear element ORF-1 protein promotes proliferation and resistance to chemotherapy in hepatocellular carcinoma. World J Gastroenterol. 2013;19:1068–78.CrossRefPubMedPubMedCentral
26.
Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423:302–5.CrossRefPubMed
27.
Wang Y, Guan Y, Wang F, et al. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro. Neurosci Lett. 2010;476:74–8.CrossRefPubMed
28.
Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063–71.CrossRefPubMedPubMedCentral
29.
Choi B, Chun E, Kim SY, et al. Notch-induced hIL-6 production facilitates the maintenance of self-renewal of hCD34+ cord blood cells through the activation of Jak-PI3K-STAT3 pathway. Am J Pathol. 2012;180:351–64.CrossRefPubMed
30.
Bhattacharyya J, Mihara K, Kitanaka A, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1. Blood Cancer J. 2012;2:e75.CrossRefPubMedPubMedCentral
31.
Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009;119:3626–36.CrossRefPubMedPubMedCentral
32.
Guo BH, Feng Y, Zhang R, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10:10.CrossRefPubMedPubMedCentral
33.
Mihic-Probst D, Kuster A, Kilgus S, et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer. 2007;121:1764–70.CrossRefPubMed
34.
Chang B, Li S, He Q, et al. Deregulation of Bmi-1 is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma. Biochim Biophys Acta. 1840;2014:3285–91.
35.
Yu Q, Su B, Liu D, et al. Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides. 2007;17:327–35.CrossRefPubMed
36.
Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178:437–51.CrossRefPubMedPubMedCentral
37.
Pon YL, Zhou HY, Cheung AN, et al. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008;68:6524–32.CrossRefPubMed
38.
Smith AP, Verrecchia A, Fagà G, et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene. 2009;28:422–30.CrossRefPubMed
39.
Liu L, Qiu M, Tan G, et al. miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. J Transl Med. 2014;12:305.CrossRefPubMedPubMedCentral
40.
Yuan W, Yuan Y, Zhang T, et al. Role of Bmi-1 in regulation of ionizing irradiation-induced epithelial-mesenchymal transition and migration of breast cancer cells. PLoS One. 2015;10:e0118799.CrossRefPubMedPubMedCentral
41.
Du R, Xia L, Ning X, et al. Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol Biol Cell. 2014;25:2650–9.CrossRefPubMedPubMedCentral
42.
Kuo S, Blair K, Rahimy E, et al. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer. 2012;12:556.CrossRefPubMedPubMedCentral
Metadata
Title
Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis
Authors
Yongsheng Zhang
Lu Han
Jian Pang
Yang Wang
Fan Feng
Qiyu Jiang
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4725-z

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells

Original Article

Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer

Original Article

CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer

Original Article

Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma

Original Article

Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer

Original Article

RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits